Women's Health

Dostarlimab-gxly (Jemperli) approved in combination with carboplatin and paclitaxel for the treatment of adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.

A study shows the first 2 years of life are a vital time to establish healthy sleep routines in infant children.

The approval of norgestrel tablets (Opill) could open the door to other prescription-to-OTC contraceptive switches, although that remains to be seen as other pharmaceutical companies weigh their options.

To slow the production of MCI and dementia, utilizing more ways of establishing the diagnoses for women can prevent the progression.

Investigators call for further public awareness of other breast cancer risk factors, besides dense breasts, which could help identify more women who are at high risk.

As the battle over abortion rages, mifepristone has become the new center of the legal fight between anti-abortion advocates and the FDA.

A lack of evidence of sex-specific recommendations results from a underrepresentation of women in cardiovascular disease-related trials.

In addition to being medication experts, pharmacists' accessibility makes them ideal clinicians to provide person-centered, gender-affirming care.

Alex Mills, PharmD, BCACP, AAHIVP, discussed his presentation at the ASHP 2023 Summer Meeting.

Positive findings in patients with advanced high-grade epithelial ovarian cancer were presented during an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting.

Research notes that modifiable lifestyle factors, such as overconsumption of food and vitamin deficiency, can affect pregnancy.

The 2023 ASCO Annual Meeting is being held in Chicago, Illinois from June 2 to 6.

Women with recurrent urinary tract infections (UTIs) are often on and off antibiotics for years, and even decades, as the only treatment available in health systems for treating UTIs.

Sexual minority populations disproportionately suffer from mental health conditions as well, which could partially impact cardiovascular health, a recent study indicates.

Findings suggest that mice derived from and breastfed by immunized mothers were capable of producing anti- pneumococcal surface protein A (PspA) specific antibodies, despite having no direct exposure to PspA.

Tackling racial disparities among health care providers can help improve disparities faced by patients.

Misinformation on YouTube promotes women wiping front to back as a non-evidence-based hygiene practice to prevent urinary tract infection.

Even before the Dobbs ruling overturned country-wide reproductive rights, the oncology field was already facing a dearth of maternal care access challenges.

Limitations on a woman’s options when pregnant and diagnosed with cancer can directly impact her ability to save her own life and preserve her fertility for future pregnancies.

The data were published during Black Maternal Health Week.

The number of female study participants was lower when the last author of the study, usually the head of the lab conducting the study, was a man.

An Independent Data Monitoring Committee recommends stopping 2 phase 3 trials early for efficacy following positive results in November 2022.

Analysis shows that babies of mothers who used drugs while pregnant were shorter at birth and weighed less during the breastfeeding stage compared with non-drug-exposed infants.

A new scientific statement from the American Heart Association notes that the process falls short for those who are not white.

Other health essentials, such as groceries, prescriptions, some OTC medications, are tax-exempt in many states.

Emerging evidence suggests that the risk of maternal mortality was more than 10-times greater among those with COVID-19 infection.

Availability of clinical trials in the gynecologic cancer care space are increasing, but it is important to be mindful of current racial disparities.

Analysis indicates that there was a larger increase of filled prescriptions for individuals who delivered by cesarean birth.

Taken together, the studies point to meaningful changes in the standard of care for patients with advanced or recurrent endometrial cancer.

The overall survival hazard ratio numerically favored niraparib in the germline BRCA mutation cohort and favored placebo in the non-germline BRCA mutation cohort in patients with platinum-sensitive recurrent ovarian cancer.